-
Posted by
Two Blokes Jul 23 -
Filed in
Stock
-
6 views
Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea , July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics.
